Who is sponsoring SIR ZOSTER?

SIR ZOSTER is sponsored by Central Adelaide Local Health Network Incorporated.

What condition does SIR ZOSTER study?

SIR ZOSTER studies Immunosuppression, Vaccine Response Impaired.

What drugs are being tested in SIR ZOSTER?

Interventions: Recombinant zoster vaccine adjuvanted (SHINGRIX).

What is the status of SIR ZOSTER?

SIR ZOSTER is currently RECRUITING.

Last reviewed 2026-04-06 · How we verify

Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients (SIR ZOSTER)

NCT06262776 NA RECRUITING

The goal of this clinical trial is to compare responses to Varicella Zoster vaccination between transplant patients on different medication regimens, and their healthy co-habitants. The main questions it aims to answer are: 1. Are there differences in vaccination immunological responses in transplant patients on different immunosuppression regimens? 2. Are there differences in vaccination immunological responses between transplant patients and their healthy co-habitants? Participants will all receive a 2-dose course of SHINGRIX recombinant Zoster vaccination, and have immunological responses measured and compared at 5 timepoints between 1 week to 1 year post-vaccination.

Details

Lead sponsor	Central Adelaide Local Health Network Incorporated
Phase	NA
Status	RECRUITING
Enrolment	160
Start date	2024-03-20
Completion	2027-12

Conditions

Immunosuppression
Vaccine Response Impaired

Interventions

Recombinant zoster vaccine adjuvanted (SHINGRIX)

Primary outcomes

Functional T cell memory — 3 weeks following second vaccine dose
ELISpot measurement of interferon gamma spot-forming units following 18-hour stimulation of peripheral blood mononuclear cells with Zoster gE protein-derived peptide array

Countries

Australia